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Abstract
Background: Bacterial infections are a cause of exacerbation of airway disease. Airway smooth
muscle cells (ASMC) are a source of inflammatory cytokines/chemokines that may propagate local
airway inflammatory responses. We hypothesize that bacteria and bacterial products could induce
cytokine/chemokine release from ASMC.
Methods: Human ASMC were grown in culture and treated with whole bacteria or pathogen
associated molecular patterns (PAMPs) for 24 or 48 h. The release of eotaxin-1, CXCL-8 or
GMCSF was measured by ELISA.
Results: Gram-negative E. coli or Gram-positive S. aureus increased the release of CXCL-8, as did
IL-1β, LPS, FSL-1 and Pam3CSK4, whereas FK565, MODLys18 or Poly I:C did not. E. coli inhibited
eotaxin-1 release under control conditions and after stimulation with IL-1β. S. aureus tended to
inhibit eotaxin-1 release stimulated with IL-1β. E. coli or LPS, but not S. aureus, induced the release
of GMCSF.
Conclusion: Gram-positive or Gram-negative bacteria activate human ASMC to release CXCL-8.
By contrast Gram-negative bacteria inhibited the release of eotaxin-1 from human ASMCs. E. coli,
but not S. aureus induced GMCSF release from cells.
Our findings that ASMC can respond directly to Gram-negative and Gram-positive bacteria by 
releasing the neutrophil selective chemokine, CXCL-8, is consistent with what we know about the 
role of neutrophil recruitment in bacterial infections in the lung. Our findings that bacteria inhibit 
the release of the eosinophil selective chemokine, eotaxin-1 may help to explain the mechanisms 
by which bacterial immunotherapy reduces allergic inflammation in the lung.
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In diseases such as asthma, the airway smooth muscle ful-
fills a contractile role. However, airway smooth muscle
cells (ASMC) can also acquire a secretory phenotype with
the ability to release inflammatory mediators including
cytokines, chemokines [1-4], and lipid hormones [5]
when stimulated with cytokines or oxidants [6,7].
The role of bacteria in airway inflammation is currently
the subject of investigation. For example, bacterial infec-
tions may exacerbate asthmatic symptoms and eradica-
tion therapy appears to provide some therapeutic benefits
[8,9]. On the other hand, low level inoculation immuno-
therapy with bacterial components may provide therapeu-
tic benefit in the treatment of allergic asthma, presumably
by redressing the balance between type1 (Th1; T helper 1)
and type 2 inflammatory pathways [10]. In addition to
asthma, it has been recognized for some time that bacte-
rial infections are the underlying cause of exacerbations in
some patients with COPD [11]. It is therefore important
that we understand how bacteria and other pathogens are
sensed by airway cells. Human ASMCs express Toll like
receptors (TLRs), including TLR2 and TLR4 [12,13]. Stim-
ulation of ASMCs with pathogen associated molecular
patterns (PAMPs) including LPS induce either low or
undetectable levels of cytokines [12-14], although the
sensing of LPS, for example, by ASMCs can be enhanced
dramatically by co-culture with monocytes [12]. However
the effects of whole bacteria on release of cytokines from
human ASMCs has not previously been studied. Moreo-
ver, the effect of bacteria or associated PAMPs on the eosi-
nophil- selective chemokines released by airway smooth
muscle is not completely understood.
In the current study we have used whole Gram-negative
Escherichia coli and Gram-positive Staphylococcus aureus as
model organisms, as well as a range of well characterized
PAMPs, to compare directly their effects on the release of
CXCL-8, which recruits neutrophils, and eotaxin-1, which
recruits eosinophils. The level of GMCSF, which is active
on both eosinophils or neutrophils was also measured.
Methods
Materials
Eotaxin-1, CXCL-8 and GMCSF enzyme-linked immuno-
sorbent assays (ELISA) DuoSet kits were purchased from
R&D Systems (Abingdon, UK). The cell culture plastic
ware was purchased from Falcon Labware (Becton Dickin-
son, Oxford, UK). The Pam3CSK4, LPS and FSL-1 were
purchased from Axxora (UK) Ltd (Nottingham, U.K). All
other tissue culture reagents and chemicals were obtained
from Sigma (Poole, UK) unless otherwise stated.
Human airway smooth muscle cell isolation and culture
Main lobar bronchi obtained from patients undergoing
lung resection for carcinoma of the bronchus were used
for dissecting human ASMC, as previously described [4].
Cells were maintained in Dulbecco's modified Eagle's
medium (DMEM) containing 10% foetal calf serum FCS
supplemented with sodium pyruvate, L-glutamine (2
mM), non-essential amino acids (1:100), penicillin (100
U ml-1)/streptomycin (100 μg ml-1) and amphotericin B
(1.5 μg ml-1) in a humidified atmosphere at 37°C in air/
CO2 (95:5 % vol/vol). Confluent cells were passaged with
0.25% trypsin and 1 mM EDTA. Cells at passages 3–7
from 6 different donors were used in the studies described
below. In pilot studies ASMC were initially characterized
by positive immunostaining for calponin, smooth muscle
α-actin and myosin heavy chain. There after they were
characterized by their typical morphology and phenotype.
Preparation of E. coli and S. aureus
E. coli, reference strain 0111.B4, and S. aureus H380 were
used. The S. aureus H380 was isolated from clinical blood
culture and stored frozen in 15% glycerol. This was
streaked onto agar plates prior to inoculation of single col-
onies into RPMI-1640 medium with 10% FCS and
glutamine at 37°C overnight. The bacteria were pelleted
by centrifugation at 800 × g then washed in sterile saline
twice. The pellets were re-suspended in sterile saline. In
order to quantify the cell density, aliquots of the bacterial
suspension were serially diluted and plated onto agar. The
bacteria in the bacterial suspensions were killed by heat
treatment for 45 min at 80°C. The resultant suspensions
were plated to confirm the sterility. Suspensions were
adjusted to 1010-1012 colony-forming units (CFUml-1)
and then frozen with 20% glycerol in aliquots before use
in cell culture experiments.
ELISAs
Measurement of GMCSF, CXCL-8 and eotaxin-1 in culture
supernatants was performed using ELISA DuoSets accord-
ing to manufactures' instructions (R&D Systems, Abing-
don, UK). Supernatants were stored at -80°C prior to
assay.
Flow cytometric analysis of TLR2 and TLR4 surface 
expression human SMC
To determine cell-surface TLR expression, 4 × 104 cells
fixed in 3.2% formaldehyde were preincubated in 50 μL
of staining buffer (0.5% BSA and 0.1% sodium azide in
PBS) containing 10% human serum and 30 μg of human
IgG (Sigma) for 30 minutes on ice to block Ig receptors as
described previously, [13]. Briefly phycoerythrin-conju-
gated anti-human TLR2 (clone TL2.1) or TLR4 (clone
HTA125), or the relevant phycoerythrin-conjugated iso-
type control antibodies (IgG2a,κ or IgG1,κ; 0.75 μg each;
eBioscience, San Diego, Calif) were then added, and thePage 2 of 8
(page number not for citation purposes)
Respiratory Research 2008, 9:30 http://respiratory-research.com/content/9/1/30cells were incubated for a further 60 minutes on ice. A
FACScan flow cytometer (Becton Dickinson Immunocy-
tometry Systems [BIDS], Oxford, United Kingdom) was
used, and typically 10,000 events were acquired in the via-
ble cell region of the forward light scatter/side light scatter
plots. Analysis was performed with CELLQuest software
(BIDS). The fluorescence signal was calculated as the geo-
metric mean fluorescence intensity of the gated ASMC
population.
Effect of whole bacteria on Eotaxin-1, CXCL-8, and 
GMCSF release
Human ASMC were plated at seeding density of 1 × 104
cells/cm2 onto 96 well plates. Confluent cells were cul-
tured in DMEM containing sodium pyruvate [4], L-
glutamine (2 mM), 10% foetal calf serum, penicillin (100
U ml-1)/streptomycin (1 μg ml-1), amphotericin B (1,5 μg
ml-1). Cells were treated in triplicate with either medium
only or a model organism for Gram-negative bacteria, (E.
coli 106–108 CFU ml-1), or Gram-positive bacteria, (S.
aureus, 106–108 CFU ml-1l), for 24 or 48 hours (h) at 37°C
in an atmosphere of CO2. The supernatants were collected
and stored at -80°C to measure the levels of eotaxin-1,
CXCL-8, and GMCSF release by using DuoSet ELISA kit
(R&D Systems) according to the manufacturers' instruc-
tions. The samples were diluted until the cytokine level
was within the linear range of the standard curve when-
ever it was required.
Effect of selective TLR2 and TLR4 ligands on chemokine 
release
Confluent cells were treated in triplicate with either
medium only or with relevant PAMPs for TLR4 (LPS,
0.01–1 μg ml-1), TLR2/TLR1 (Pam3CSK4), TLR2/TLR6
(FSL-1, 10–1000 ng ml-1), NOD1 (FK565, 10 nM and 100
nM) or NOD2 (MDPLys18, 10 nM and 100 nM) for 24 h
or 48 h at 37°C in a CO2 incubator.
Effect of whole bacteria or TLR2/TLR4 ligand on IL-1β 
induced chemokine release
Confluent cells were treated with Gram-negative (E. coli,
107–108 CFU ml-1), Gram-positive (S. aureus, 107–108
CFU ml-1), LPS (0.01–1 μg ml-1l) or FK565, 10 nM and
100 nM)I in the presence and absence of IL-1β (1 ng ml-
1) for 24 h before chemokines were measured in the
supernatant as described above.
Effect of selective TLR3 ligand Poly I:C on chemokine 
release
Cells were treated in triplicate with either medium only or
with Poly I:C (0.01 -10 μg/ml) alone or Poly I:C (1 or μg/
ml) in the presence of E. coli (106 CFU ml-1), S. aureus (106
CFU ml-1) or LPS at 0.01 μg ml-1 for 24 h before chemok-
ine release was measured as described earlier.
Cell number and cell viability
The cell viability was assessed by the mitochondrial-
dependent reduction of MTT to formazan on the remain-
ing cells following all treatments mentioned above.
Briefly, following the removal of supernatant, the remain-
ing cells were incubated with 1 mg ml-1 MTT in serum free
medium at 37°C for 15 min. The MTT was removed and
DMSO was added. The OD was read at 550 nm.
Data and Statistical Analysis
Data are presented as mean ± SEM. Data were compared
using one-way analysis of variance (ANOVA) followed by
Newman-Keuls post-hoc t-test to determine statistical dif-
ferences after multiple comparisons using Prism software.
A probability value of less than 0.05 was considered sig-
nificant.
Results
Effect of Gram-negative E. coli and associated PAMPs on 
release of CXCL-8
E. coli activates PRRs including TLR4 and NOD1. LPS is a
PAMP for TLR4 and FK565 is a PAMP for NOD1. Under
control culture conditions, human ASMCs released rela-
tively low, but detectable levels of CXCL-8. When E. coli
(106 to 108 CFU ml-1) was added to human ASMCs, the
release of CXCL-8 was increased at 24 (Figure 1) or 48
hours (table 1). In line with this, cells stimulated with LPS
(0.01 to 1 μg ml-1) released increased levels of CXCL-8
(Figure 1; table 1). By contrast, FK565 (10 to 100 nM), did
not affect CXCL-8 release when administered alone (Fig-
ure 1). In separate experiments, it was noted that FK565
had no interaction with LPS in the release of CXCL-8 from
human ASMCs (control, 48.39 ± 17.9; plus LPS, 161.7 ±
21.9; plus FK565, 23.07 ± 8.3 LPS+FK565, 123.9 ± 17.3, n
= 3).
Effect of Gram-positive S. aureus and associated PAMPs 
on release of CXCL-8 from human ASMCs
S. aureus activates PRRs including TLR2/TLR1, TLR2/TLR6
and NOD2. Pam3CSK4, FSL-1 and MDPLys18 are PAMPs
for TLR2/TLR1, TLR2/TLR6 and NOD2 respectively. S.
aureus (106 to 108 CFU ml-1) stimulated the release of
CXCL-8 from human ASMCs at 24 (Figure 1) and 48 h
(table 1). Similarly Pam3CSK4 (3 to 300 ng ml-1) or FSL-
1 (10 to 1000 ng ml-1) increased the release of CXCL-8 at
24 (Figure 1) and 48 h (table 2). By contrast, MDPLys18
(10 to 100 ng ml-1) had no significant effect on the release
of CXCL-8 (Figure 1).
Effect of Gram-negative E. coli and associated PAMPs on 
release of eotaxin-1 from human ASMCs
Under control culture conditions, ASMCs released rela-
tively low or undetectable levels of eotaxin-1. When E. coli
(106 to 108 CFU ml-1) was added to human ASMCs, in
experiments from cells of donors where 'basal' levels werePage 3 of 8
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not shown). In subsequent experiments, cells were stimu-
lated with IL-1β in order to induce eotaxin-1 release and
the effects of co- treatment with bacteria or PAMPs were
studied. E. coli induced a concentration dependent reduc-
tion in the release of eotaxin-1 stimulated with IL-1β. This
was significant at 108 CFU ml-1 (Figure 2). Neither LPS,
nor FK565 given alone or in combination affected the
release of eotaxin-1 induced by IL-1β (data not shown).
Effect of Gram-positive S. aureus and associated PAMPs 
on release of eotaxin-1 from human ASMCs
Similar to observations with E. coli, S. aureus (107 and 108
CFU ml-1) did not induce the release of eotaxin-1 from
human ASMCs (Figure 2). Furthermore, when cells were
co-stimulated with IL-1β, S. aureus tended to reduce
eotaxin-1 release, although this did not reach statistical
significance (Figure 2). In line with observations from
Table 2
Treatments Concentrations Mean ± s.e.m
control 0 248.3 ± 76.44
S. aureus (CFU ml-1) 106 328.8 ± 132.1
107 170.0 ± 56.09
108 2564 ± 1062
PAM 3 (ng ml-1) 3 405.3 ± 103.0
30 2108 ± 531.5
300 7994 ± 2178.0
FSL1 (ng ml-1) 10 370.6 ± 144.4
100 509.0 ± 214.4
1000 3792 ± 1379
MDPLys18 (10 nM) 10 218.1 ± 95.11
100 444.1 ± 143.1
Effect of Gram-positive bacteria and associated PAMPs on CXCL-8 
release from human ASMCs over 48 h. ASMCs were treated either 
Gram-positive bacteria S. aureus, (106–108 CFU ml-1), Pam3CSK4 (3 – 
300 ng ml-1), FSL-1, (10 – 1000 ng ml-1) or MDPLys18 (10 nM and 100 
nM). The data represent the mean ± SEM of triplicate of three 
different donors.
Effect of bacteria and associated PAMPs on CXCL-8 release from human ASMCs over 24 hFigure 1
Effect of bacteria and associated PAMPs on CXCL-8 release from human ASMCs over 24 h. Panel A, human 
ASMCs treated with Gram-negative bacteria, LPS or FK565. Panel B, cells treated with Gram-positive bacteria, Pam3CSK4, FSL-
1, MDPLys18. Data represent mean ± SEM for triplicate of three different donors. * p < 0.05; **p < 0.01; ***p < 0.001 com-
pared with un-stimulated control (medium only).
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Table 1
Treatments Concentrations Mean ± s.e.m
control 0 298 ± 71.17
E. coli (CFU ml-1) 106 4566 ± 1218
107 7060 ± 1866
108 17130 ± 5373
LPS (μg ml-1) 0.01 2500 ± 739.5
0.1 4392 ± 1131
1 4217 ± 1050
FK565 (10 nM) 10 177.3 ± 88.16
100 150.8 ± 67.31
Effect of Gram-negative bacteria and associated PAMPs on CXCL-8 
release from human ASMCs over 48 h. ASMCs were treated with 
either bacteria Gram-negative E. coli, (106–108 CFU ml-1), LPS, (0.01–1 
μg ml-1) or FK565, (10 nM and 100 nM). The data represent the mean 
± SEM from triplicate of three different donors.Page 4 of 8
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MDPLys18 affected eotaxin-1 release by human ASMCs
(data not shown).
Effect of Gram-negative E. coli or Gram-positive S. aureus 
bacteria on GMCSF release by human ASMCs
Under control culture conditions, human ASMCs released
low or undetectable levels of GMCSF. Stimulation of cells
with E. coli (107 and 108 CFU ml-1) induced increased
release of GMCSF (Figure 3). However, S. aureus (107 or
108 CFU ml-1) had no effect on the release of GMCSF (Fig-
ure 3). In the presence of IL-1β, GMCSF release was
increased. Neither E. coli nor S. aureus had any additional
effect on GMCSF release in cells stimulated with IL-1β
(Figure 3).
Effect of Poly I:C on chemokine release by human ASMCs
Viral PAMPs activate intracellular PRRs. Poly I:C is a syn-
thetic form of viral dsRNA and a selective ligand for TLR3.
Poly I:C (0.01 -10 μg/ml) had no effect on the release of
CXCL-8 or eotaxin-1 from human ASMCs stimulated for
24 h (data not shown). When cells were co-treated with
Effect of bacteria on GMCSF release from human ASMCs over 24 hFigure 3
Effect of bacteria on GMCSF release from human ASMCs over 24 h. ASMCs treated with Gram-negative bacteria, E. 
coli, (panel A), or Gram-positive bacteria S. aureus (panel B) in the presence or absence of IL-1β (1 ng ml-1). The data represent 
the mean ± SEM of triplicate of three different donors. ***p < 0.001 compared with un-stimulated control (medium only).
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Effect of Gram-negative or Gram-positive bacteria on eotaxin-1 release in human ASMC over 24 hFigure 2
Effect of Gram-negative or Gram-positive bacteria on eotaxin-1 release in human ASMC over 24 h. ASMCs 
were treated with E. coli (panel A), or S. aureus (panel B) in the present or absent of IL-1β (1 ng ml-1). Data are mean ± SEM.; 
from triplicate of three different donors. * p < 0.05 compared with control (cell stimulated with IL-1β only).
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which did not reach statistical significance, for eotaxin-1
and CXCL-8 to be increased (Figure 4).
Expression of TLR2 and TLR4 by human ASMCs
As we have shown previously [13], human ASMCs express
detectable levels of TLR2 or TLR4 (Table 3). Incubation of
cells with whole Gram-positive or Gram-negative bacteria
did not significantly alter levels of TLR expression (Table
3).
Discussion
In the current study we demonstrate that human ASMCs
respond directly to Gram-negative or Gram-positive bac-
teria. We also show that there is a differential relationship
between the release of CXCL-8 and eotaxin-1 by these
cells when stimulated with bacteria.
Gram-negative E. coli or Gram-positive S. aureus activated
human ASMCs to release CXCL-8. CXCL-8 is a potent che-
moatractant for neutrophils. Recruitment of neutrophils
is an early event at the site of bacterial infection and these
observations identify an innate immune function of
ASMCs which may be relevant in conditions such as
asthma or COPD.
In most cells, the effects of Gram-negative bacteria can be
mimicked by LPS, which activates TLR4 [15]. Gram-nega-
tive bacteria also contain peptidoglycan which can acti-
vate NOD receptors. The effect of E. coli on CXCL-8 by
human airway smooth muscle cells was mimicked by LPS,
but not by FK565, which activates NOD1 receptors. In
some cell types LPS synergizes with FK565 to activate cells
[16,17]. However, in the current study using ASMCs, we
found no evidence for interaction between these two
pathways. These observations suggest that the ability of
Gram-negative E. coli to stimulate airway smooth muscle
cells to release CXCL-8 is mediated by TLR4 and not
NOD1 receptor activation.
Gram-positive bacteria contain PAMPs for TLR2, which
can heterodimerize with either TLR1 or TLR6 [18]. In our
hands, activation of either the TLR2/TLR1, with
Pam3CSK4 or TLR2/TLR6, with FSL-1 resulted in a stimu-
lation of ASMCs and release of CXCL-8. Peptidoglycan
from Gram-positive bacteria activates mainly NOD2
[16,19]. MDPLys18 which is a selective ligand for NOD2,
had no effect on CXCL-8 release by airway smooth muscle
cell; these observations suggest that the effects of S. aureus
on airway smooth muscle are mediated by TLR2 and not
by NOD receptor activation.
Table 3
Treatments TLR2 (MFIr) TLR4 (MFIr)
control 1.34 ± 0.1 1.81 ± 0.1
E. coli 1.4 ± 0.03 1.66 ± 0.1
S. aureus 1.3 ± 0.05 1.59 ± 0.04
Flow-cytometric analysis of cell surface TLR2 and TLR4 protein in 
human ASMC. Cells were treated with E. Coli or S. Aureus (108 CFU/
ml) for 48 hrs. Data is expressed as ratio of mean fluorescence 
intensity (MFIr) of cells stained with specific TLR2 or TLR4 antibodies 
and cells stained with the relevant isotype control antibodies. The 
data is the mean ± SEM of n = 3–4 ASMC donors.
Effect of selective Poly I:C on chemokine release from human ASMCFigure 4
Effect of selective Poly I:C on chemokine release from human ASMC. ASMCs were treated in triplicate for 24 h with 
either medium only or with TLR3 (Poly I:C) alone or in the present of Gram-negative bacteria, E. coli, or Gram-positive bacte-
ria, S. aureus or LPS (Panels A&B). The data represent the mean ± SEM of three different donors.
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found that E. coli, but not S. aureus, increased the release
of GMCSF by human airway smooth muscle cells. In other
cells, the effects of E. coli are mediated principally by TLR4
and those of S. aureus by TLR2 [20]. TLR4 recruits both
TRIF/TRAM and MyD88/MAL adapter protein pathways.
TLR2, on the other hand, recruits MyD88/MAL only. It
may well be, therefore, that CXCL-8 is a MyD88/MAL-
dependent gene whereas GMCSF, like M-CSF [21], or
NOSII [22,23], is independent of the MyD88 pathway
and is mediated by TRIF/TRAM.
By contrast to results obtained with CXCL-8, we found
that bacteria did not stimulate the release of eotaxin-1. In
fact, in cells co-treated with IL-1β, Gram-negative E. coli
inhibited eotaxin-1 release. A similar trend was seen for
cells stimulated with IL-1β and S. aureus. If the observa-
tions we make here with cells in vitro translate to the in vivo
situation, we may expect bacteria to reduce eotaxin-1 in
the airways, limit the numbers of eosinophils recruited
and reduce the associated respiratory symptoms in allergic
airway disease. Interestingly, recent studies have shown
that bacterial DNA immunotherapy can successfully
inhibit eosinophil recruitment into the airways in models
of allergic lung disease [24]. In the current study, we
found that the inhibitory effects of E. coli, on eotaxin-1
release were not mimicked by LPS or by FK565 in our
experimental conditions. Whilst not tested directly, our
observations are consistent with the effects of E. coli on
eotaxin-1 release being mediated by DNA and not by
TLR4 or NOD receptors. Our data shows that treatment of
cells with Poly:IC did not induce CXCL-8 or eotaxin
release. We have shown previously that Poly I:C at a con-
centration of 25 μg/ml induced the release of eotaxin and
IL-8 from airway smooth muscle cells [13], but in the cur-
rent study, we did not find an effect of Poly I:C at 10 μg/
ml although eotaxin release has been reported at this con-
centration [25]. This may be due to the fact that we treated
the cells under different conditions, that is, in the pres-
ence of serum, while the other studies used serum-free
conditions.
It is important to note that the observations we report
here may well have important implications for other res-
piratory conditions in which bacterial infections are prev-
alent such as cystic fibrosis. In cystic fibrosis, colonisation
of the lungs with bacteria is known to contribute to exac-
erbations. Moreover, remodelling of airway smooth mus-
cle in this condition [26-28] may lead to an alteration in
the balance of chemokine release in response to bacteria.
Conclusion
We show that whole Gram-positive or Gram-negative bac-
teria activate human airway smooth muscle cells to release
CXCL-8. Using selective PAMPs, we establish that the
effects of whole bacteria on CXCL-8 are likely to be medi-
ated by TLRs and not by NOD receptors. By contrast to
CXCL-8, we found that bacteria inhibited the release of
eotaxin-1 from human ASMCs. In the case of eotaxin-1
release, the effects of Gram-negative bacteria did not
appear to be mediated by TLR4 or NOD pathways. These
observations establish a clear but complex innate immune
function of ASMCs with regard to bacterial infections.
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